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August 2011582 Abstractsthe clinical strength and statistical significance of IMT changes associated
with cardiovascular outcomes when compared tomore direct atherosclerotic
risk factors. It may also be, that atherosclerosis in the carotid artery, is not
generally representative of atherosclerosis throughout the body. Atheroscle-
rotic plaques in the carotid artery grow longitudinally at twice the rate that
they grow in thickness. Therefore, IMT may be a less sensitive measure of
plaque evolution than total plaque burden (Mackinnon AD, et al. Stroke
2004;35:2150-4). The bottom line, however, is that while IMT increase
indicates increased cardiovascular risk, changes in IMT induced by drug
therapy do not appear to reflect clinical outcome.
Outcomes of Endovascular Repair of Ruptured Descending Thoracic
Aortic Aneurysms
Jonker FH, Verhagen HJ, Lin PH, et al. Circulation 2010;121:2718-23.
Conclusions: Endovascular repair of ruptured descending thoracic
aortic aneurysms (TAAs) provides encouraging results but is associated with
a significant rate of neurologic complications and a relatively high rate of
endoleak.
Summary: Ruptured TAAs are relatively rare with reported an inci-
dence of only about 5 per 100,000. Mortality is high and is thought to
exceed 90% (Johannson G. J Vasc Surg 1995;21:985-8). There is little
information on endovascular treatment of ruptured TAAs. Ruptures of true
degenerative TAAs are often lumped in other series combining penetrating
aortic ulcers, thoracic aortic trauma and complications of type B dissection.
The authors accumulated a “pure” series of ruptured descending TAAs by
identifying patients treated with endovascular repair for ruptured AA at 7
different centers between July 2002 and July 2009. There were 87 patients
in this retrospective study with a mean age of 69.8  12 years and 69.0%
were men. At presentation 40.2% were hemodynamically unstable and
21.8% were in hypovolemic shock. Following endovascular repair mortality
was 18.4%. Increased 30-day mortality after adjusting for age, was associated
with hypovolemic shock (OR, 4.75; 95% CI, 1.37 to 16.5; P  .014) and
hemothorax on admission (OR, 6.65; 95% CI, 1.64 to 27.1; P  .008).
Ruptured TAA s were successfully excluded during TEVAR in 95.4%. Stroke
occurred in 8% (n  7). Four patients died of stroke. Post operative
paraplegia occurred in 8% (n  7) and was permanent in 2 patients and
transient in 5. There was an 18.4% incidence of endoleak during the first 30
days (n  16) with type 1 of endoleaks occurring in 10 patients, type 2
endoleaks in 5 patients and a type 3 endoleak in one patient. There were 2
late aortic esophageal fistulas that were fatal. Estimated freedom from
aneurysm related death or intervention was 54.9% at 4 years.
Comment: Short term mortality rates of TEVAR treatment of de-
scending TAA rupture compares favorably with open repair of descending
TAA rupture (Schermerhorn ML, et al. J Vasc Surg 2008;48:821-7).
Endovascular repair of a descending ruptured TAA does appear to be
associated with a high rate of neurologic and procedurally related complica-
tions, particularly type 1 endoleak. The data make it reasonably to consider
TEVAR for repair of a ruptured descending TAA but morbidity and mor-
tality are still significant.
Risk of Early Carotid Endarterectomy for Symptomatic Carotid
Stenosis
Brinjikji W, Rabinstein AA, Meyer FB, et al. Stroke 2010;41:2186-90.
Conclusion: Carotid endarterectomy (CEA) can be performed with
slightly increased, but acceptable, risk in symptomatic patients within two
weeks of stroke or transient ischemic attack.
Summary:Current guidelines from the American Academy of Neurol-
ogy and the American Heart Association indicate patients with symptomatic
carotid stenosis should preferentially undergo CEA within 2 weeks of the
symptomatic event (Chaturvedi S, et al. Neurology 2005;65:794-801, and
Sacco RL, et al. Stroke 2006;37:577-617). However many patients are not
operated within 2 weeks. In addition, traditional “surgical wisdom” has
shied away from acute operation especially in stroke patients for fear of a
higher incidence of complications (Naylor AR. Surgeon 2007;5:23-30).
The authors examined their institutional experience with CEA with
particular analysis of symptomatic patients operated within 2 weeks of
symptoms. Symptomatic patients were not considered for early CEA if they
had an infarct involving more than one third of the middle cerebral artery
territory or if a patient had a fixed disabling deficit or an unstable medical
condition. When those conditions were not present patients were operated
soon after evaluation irrespective of the interval from the symptomatic event.
The authors felt delays were usually related to delayed referral after symptom
onset.
The patients analyzed were those operated between January 2004 and
May 2009. Patients were divided into three groups. Group 1 were asymp-
tomatic, group 2 were symptomatic patients operated 2 weeks after their
symptom, and group 3 were symptomatic patients operated on 2 weeks
after their symptom (transient ischemic attack or stroke). Primary outcome
was any myocardial infarction, stroke, or death within 30 days of the
c
operation. A secondary endpoint was transient ischemic attack within 30
ays postoperatively.
There were 532 carotid endarterectomies performed in 507 patients.
here were 500 patients with 525 CEA’s who had 30 day follow up. There
ere 278 in group 1, 105 in group 2, and 142 in group 3. The primary
utcome occurred in 5 patients in group 1 (1.8%); 1 patient in group 2
1.0%); and 6 patients in group 3 (4.2%). There were no significant differ-
nces in the rate of primary outcome among the three groups (P  .17).
here was also no significant difference comparing group 2 to group 3 (P
24).
Comment: This study has all the limitations of a single institution
etrospective review. The biggest problem is insuring patients in group 2 and
roup 3 did in fact only differ primarily by referral pattern and not by other
ore pertinentmedical conditions. The percentage of patients with stroke in
roup 2 and group 3 was similar (36.2% versus 35.2%), but we really don’t
now whether the severity of the strokes were the same and whether
erioperative management and other co-morbidities were the same. Never-
heless, this study lends further support to a policy of performance of CEA in
elected patients shortly after the onset of a neurologic symptom.
uperior Nationwide Outcomes of Endovascular versus Open Repair
or Isolated Descending Thoracic Aortic Aneurysm in 11,669 Patients
opaldas RR, Huh J, Dao TK, et. al. J Thorac Cardiovas Surg 2010;140:
001-10.
Conclusion: Compared with open aortic repair (OAR) thoracic endo-
ascular aneurysm repair (TEVAR) is associated with shorter hospital stay,
imilar mortalities, fewer complications, and increased hospital charges.
Summary: The first endovascular prosthesis was approved in 2005 for
horacic endovascular aneurysm repair in the United States. The technology
as been widely adopted but there is little information available on TEVAR
ationwide outcomes for treatment of descending isolated thoracic aortic
neurysm (TAA). The authors therefore compared in hospital outcomes of
EVAR and open descending TAA repairs performed in the United States
uring the initial 3 years following approval of the GORETAG device. They
sed nationwide data to identify patients who had undergone surgery for
solated descending TAA from 2006-2007. Patients treated for aortic dis-
ection or rupture or who underwent simultaneous treatment of other aortic
egments were excluded. There were 11,669 patients analyzed and 9,106
ad conventional open aneurysm repair (OAR) and 2,563 had TEVAR.
atients were compared for mortality and hospital stay as well as discharge
tatus, morbidity, and hospital charges.
Patients undergoing TEVAR were older (69.5  12.7 versus 60.2 
4.2 years; P .001) and had higher preoperative morbidity. Length of stay
as shorter for TEVAR patients (7.7  11 versus 8.8  7.9 days). Unad-
usted mortality was similar for TEVAR (2.3%) and OAR (2.2%; P  1.0).
here were similar proportions of non elective interventions in the two
roups (TEVAR 15.9% versus OAR 15.8%; P .9). Risk adjusted mortality
ates with TEVAR and OAR were similar. TEVAR patients, however, had
0% fewer complications (OR, 0.39; P  .001). TEVAR patients were 4
imes more likely to have a routine discharge home than OAR patients.
EVAR hospital charges were greater by $6713 (95% CI, 1869- 11,556;
 .001).
Comment: Surgical procedures with good outcomes and that are
easy” to perform are adopted widely. More difficult procedures are gener-
lly restricted to high volume centers. Wide spread adoption of TEVAR is
ppropriate. Even though TEVAR was selectively performed in patients
lmost a decade older than the OAR patients, outcomes were comparable, if
ot superior, for TEVAR versus OAR with TEVAR having significantly
etter risk adjusted morbidity, primarily from lower incidences of neuro-
ogic, respiratory and pulmonary complications. Additional data is needed to
etermine whether TEVAR has volume dependent outcomes, or like endo-
ascular abdominal aortic aneurysm repair, can be performed with relatively
ow morbidity in low volume hospitals. Such data is needed to determine
hether thoracic aortic aneurysm patients should be treated in centers
edicated to treatment of aortic disease or if TEVAR will permit more wide
pread treatment of thoracic aortic pathology in community and smaller
egional hospitals.
iming of Preoperative Beta-Blocker Treatment in Vascular Surgery
atients Influence on Postoperative Outcome
lu WJ, van Kujik JP, Chonchol M, et.al. J Am Coll Cardiol 2010;56:
922-9.
Conclusion: -blocker treatment initiated more than one week before
ascular surgery is associated with lower preoperative heart rate and im-
roved cardiovascular outcomes compared to treatment initiated less than
ne week preoperatively.
Summary:Most randomized control trials and observational studies of
-blocker therapy in vascular surgical patients indicate a favorable effect on
ardiovascular outcome with perioperative -blockers. Benefit may be sec-
ndary to heart rate control, reduction of systolic pressure, reduction in
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Volume 54, Number 2 Abstracts 583ventricular contractility or anti- arrhythmic properties of -blockers.
-blockers may also prevent plaque rupture in coronary arteries by reducing
mechanical stress on the coronary plaques (Lopez-Sendon J, et.al. Eur
Heart J 2004:25:1341-62) and may decrease circulating levels of C-reactive
protein thereby stabilizing coronary plaques through anti inflammatory
mechanisms (Jenkins NP, et.al. Am JMed 2002;112:269-74). The duration
of -blocker treatment before vascular surgery and its effect on cardiovas-
cular outcome in vascular surgical patients has not, however, been specifi-
cally studied. The authors sought to evaluate the timing of -blocker
initiation and its influence on preoperative heart rate, C-reactive protein
levels, and post operative outcome in a cohort of patients undergoing
vascular surgery.
Preoperative heart rate and high sensitive C-reactive protein (CRP)
levels were recorded in 940 vascular surgical patients with respect to time of
the -blocker initiation before surgery. Initiation of -blocker’s was divided
into three time periods, 1 week prior to surgery, 1-4 weeks prior to
surgery, and 4 weeks prior to surgery. Troponin- T measurements were
made pre and post operatively and electrocardiograms were also routinely
obtained. The endpoints of the study included 30 day cardiac events (a
composite of myocardial infarction and cardiac mortality) as well as long
term mortality. The relationship between duration of -blocker treatment
and outcome was evaluated by multi-variant regression analysis adjusted to
cardiac risk factors.
There were 158 patients (17%) who had -blockers initiated 1 week
prior to vascular surgery. There were 393 patients (42%) who had -blocker
therapy initiated between 1 and 4 weeks prior to vascular surgery and 389
patients (41%) who had -blocker therapy more than 4 weeks prior to
vascular surgery. In comparing heart-rates of new patients with -blocker
therapy initiated  1 week preoperatively to those patients where therapy
was initiated 1 week preoperatively there was a significant decrease in
median heart rate in the patients with therapy initiated 1 week preopera-
tively (74  17 beats/min versus 66  15 beats/min; P  0.001). Median
CRP levels were not different in patients in which -blocker therapy was
initiated 1 week preoperatively compared to patients in which -blocker
therapy was initiated1 week preoperatively (P .782). There was a lower
incidence of 30 day cardiac events in patients in which -blocker therapy was
initiated 1 week to 4 weeks or 4 weeks prior to surgery compared to
those where therapy was initiated  1 week prior to vascular surgery (OR,
0.46; 95% CI, 0.27-0.76; OR, 0.48; 95% CI, 0.29-0.79). There was also
improved long term mortality in patients with -blocker therapy initiated
between 1 and 4 weeks and4 weeks preoperatively compared to those with
therapy initiated1 week preoperatively (HR, 0.52; 95% CI, 021-0.67; and
HR, 0.50; 95% CI, 0.25-0.71, respectively). There were there perioperative
strokes in the patients in whom -blocker therapy was initiated 1 week
preoperatively versus 4 perioperative strokes in the patients where -blocker
therapy was initiated more than 1 week preoperatively (P  .021).
Comment: There appear to be significant advantages to initiating
-blocker therapy more than 1 week preoperatively in patients undergoing
vascular surgery. A number of questions do remain. Could one prescribe
higher -blocker doses to achieve more rapid heart rate control and then be
able to routinely start treatment 1 week preoperatively? Or, will more
aggressive up titration of -blocker therapy perhaps lead to potential over-
dosing of the drug and more side effects? Indeed, the POSIE trial suggested
that higher -blocker doses without up -titration in surgical patients can lead
to an increased incidence of bradycardia, hypertension and stroke. Clearly,
trying to initiate -blocker therapy with monitoring and up titration
of therapy in less than a week would poses logistical difficulties. Another
question is whether to use perioperative -blockers in -blocker naïve
d
watients who require urgent vascular surgery? What this trial tells us is that in
lective cases of vascular surgery one should start -blockers more than one
eek prior to surgery. What to do with -blocker naïve patients who require
rgent operation remains an open question as does how rapidly can -block-
rs be safely introduced to the preoperative vascular surgery patient.
omen with Peripheral Arterial Disease Experience Faster Functional
ecline than Men with Peripheral Arterial Disease
cDermott MM, Ferrucci L, Liu K, et al. J Am Coll Cardiol 2011;57:707-
4.
Conclusion: Women with peripheral arterial disease (PAD) have
reater loss of mobility and faster functional decline than men with PAD.
ifferences may be attributable to women with PAD having smaller baseline
alf muscle area than men with PAD.
Summary: The prevalence of PAD in older patients is the same in
omen as in men and may be higher (Vavra AK. Women’s Health 2009;5:
69-83). It has been demonstrated women with PAD have decreased lower
xtremity strength and greater functional impairment than men with PAD
McDermott MM. J Am Geriatric Soc 2003;51:222-8). In this study the
uthors determined whether there are sex differences in rate of functional
ecline over time and whether there are differences in rates of change of calf
uscles characteristics over time between men and women with PAD.
This was a longitudinal observational study. Rates of mobility loss,
ecline in six minute walk performance, and decline in walking velocity
etween men and women with PAD were determined at baseline and at 4
ears of follow up. Baseline measurements of calf muscle characteristics and
eg strength and changes in these muscle parameters between women and
en with PAD were also determined at baseline and at 4 years of follow up.
here were 380 men and women with PAD who completed a six minute
alk test and were assessed for mobility, disability, and who underwent an
valuation of 4 meter walking velocity at baseline and annually for up to 4
ears. Calf muscle characteristics were measured biannually with computed
omography. Outcomes included becoming unable to walk for 6 minutes
ontinuously among patients who could walk continuously for 6 minutes at
aseline. An additional outcome was mobility loss defined as becoming
nable to walk for one-quarter mile or to walk up and down one flight of
tairs without assistance. Adjustments were made for race, age, body mass
ndex, the ankle brachial index, physical activity, comorbidities, and other
onfounders.
At 4 years of follow-up, women were more likely to become unable to
alk for 6 minutes continuously (HR, 2.3; 95%CI, 1.3-4.06; P  .004).
omen were more likely to develop mobility disability (HR, 1.79; 95% CI,
.3-3.03; P .03). Women also had faster declines in walking velocity (P
022) and distance achieved during the 6 minute walk (P  .041). After
djustment for a baseline sex differences in calf muscle area sex differences in
unctional decline were no longer statically significant.
Comment: In this study women had smaller calf muscle area and lower
alf muscle densities and less knee extension strength at baseline compared
o men. With adjustments in the analysis sex differences in functional decline
etween women and men with PAD disappeared. This suggests poorer
unctional performance at baseline among women compared to men results
n women being closer at baseline to thresholds for mobility loss and physical
ysfunction. Interventions to improve lower extremity strength among
omen with PAD may slow their functional decline.
